Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

(2009) Michael Dickinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Development of the pan-DAC inhibitor panobinostat (LBH589): Successes and challenges

(2009) Peter Atadja   CANCER LETTERS

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

(2009) H Miles Prince et al.   Future Oncology

HDAC family: What are the cancer relevant targets?

(2008) Olaf Witt et al.   CANCER LETTERS

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

Modeling, Prediction, and in Vitro in Vivo Correlation of CYP3A4 Induction

(2008) M. Shou et al.   DRUG METABOLISM AND DISPOSITION

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas

(2008) Omar Khan et al.   Nature clinical practice. Oncology